Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Chronic Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

for
Breast Cancer Females
Location: Toronto
Sponsor: University of Toronto

Sex: Female

Age: 0+

Code: NCT06776458

Recruiting
Active & Responsive

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

for
HER2-positive Metastatic Breast Cancer
Location: Westerly RI, Waterford CT, Guilford CT, Glastonbury CT,
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All

Age: 18+

Code: NCT06551116

Recruiting
Active & Responsive

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care

for
Breast Carcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 30+

Code: NCT04794816

Recruiting
Active & Responsive

Multisite Implementation of COMPRENDO

for
Pediatric Cancer
Location: Boston MA, Birmingham AL, San Diego CA,
Sponsor: University of California, San Diego

Sex: All

Age: 18+

Code: NCT06055296

Recruiting
Active & Responsive

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for
Breast Neoplasms, Breast Cancer
Location: Norfolk VA, Nashville TN, Skokie IL, Houston TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06797635

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Improving Care for Rural Patients With Solid Tumors

for
Lung Cancer, Head and Neck Cancer, Thyroid Cancer,
Location: Greeley CO, Aurora CO, Loveland CO, Fort Collins CO,
Sponsor: University of Colorado, Denver

Sex: All

Age: 18 - 70+

Code: NCT04916990

Recruiting
Active & Responsive

CARE Study: Cancer, Asian Americans, and Relationship Enrichment

for
Neoplasm
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 21 - 70+

Code: NCT06782581

Recruiting
Active & Responsive

Susan G. Komen's ShareForCures

for
Breast Cancer
Location: Dallas TX
Sponsor: Susan G. Komen Breast Cancer Foundation

Sex: All

Age: 18+

Code: NCT05654246

Recruiting
Active & Responsive

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT05661201

Phase 1, Recruiting
Active & Responsive

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT01050504

Recruiting
Active & Responsive

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

for
Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
Location: Sarasota FL, Nashville TN, Beverly Hills CA
Sponsor: MBQ Pharma

Sex: All

Age: 21+

Code: NCT06075810

Phase 1, Recruiting
Active & Responsive

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: Female

Age: 18+

Code: NCT05417308

Early Phase 1, Recruiting
Active & Responsive

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

for
Cancer, Adjustment Disorders
Location: Rockville MD
Sponsor: Sunstone Medical

Sex: All

Age: 18+

Code: NCT05584826

Phase 2, Recruiting
Active & Responsive

PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery.

for
Frailty, Oncology Problem, Cognitive Impairment
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: All

Age: 70+

Code: NCT06022666

Recruiting
Active & Responsive

Study of 18F-FFNP Breast PET/MRI

for
Breast Cancer
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: Female

Age: 18+

Code: NCT06086704

Phase 2, Recruiting
Active & Responsive

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

for
Breast Cancer Stage I, Breast Cancer Stage II,
Location: Washington D.C. DC
Sponsor: George Washington University

Sex: All

Age: 21+

Code: NCT06806930

Phase 2, Recruiting
Active & Responsive

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

for
Solid Tumor
Location: Pittsburgh PA, Atlanta GA, St Louis MO, Houston TX
Sponsor: Emory University

Sex: All

Age: 1 - 30

Code: NCT04469530

Phase 2, Recruiting
Active & Responsive

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

for
Breast Atypical Hyperplasia, Breast Carcinoma,
Location: Columbus OH, Chicago IL, Kansas City KS, Duarte CA
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 35+

Code: NCT05941520

Phase 2, Recruiting
Active & Responsive

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

for
Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome,
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All

Age: 0+

Code: NCT03160274

Recruiting
Active & Responsive

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors
Location: Fairfax VA, Houston TX, Fort Worth TX, San Antonio TX,
Sponsor: Antares Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT07767474

Phase 1, Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial